News Release

Nature Article Cites Cleanascite™ to Investigate Serum Lipid Factors Linking Ageing and Cancer Progression

MONMOUTH JUNCTION, NJ , August 27, 2020 -- Biotech Support Group reports on an article published in Nature, describing the simplicity and efficiency of their lipid clearance sample preparation technology for studying aggressive factors associated with serum and ageing. The citation is:

Gomes, Ana P., et al. "Age-induced accumulation of methylmalonic acid promotes tumour progression." Nature (2020): 1-5. https://doi.org/10.1038/s41586-020-2630-0

The risk of cancer and associated mortality increases substantially in humans from the age of 65 years onwards. The authors describe how metabolic alterations that occur with age can produce a systemic environment that favors the progression of tumors. Specifically, that methylmalonic acid (MMA), a by-product of propionate metabolism, is upregulated in the serum of older people and functions as a mediator of tumor progression. To support this analysis, the authors state “HS (human serum) samples were manipulated to assess the components … that might facilitate entrance of MMA into cells. To delipidate the HS, Cleanascite Lipid Removal Reagent (Biotech Support Group) was used according to the manufacturer’s protocol …, using a 1:4 volume ratio of Cleanascite reagent to sample”.



The authors conclude that depletion of lipidic structures from serum taken from an older population, resulted in a reduction in total serum MMA levels and was sufficient to abrogate the pro-aggressive phenotype. The data show that MMA, complexed with lipidic structures, is a circulatory factor that contributes to the pro-aggressive effects of ageing in cancer cells and is sufficient to drive tumor progression and aggressiveness. Thus, MMA is a promising therapeutic target for advanced carcinomas.

“Its rewarding to see another reference whereby Cleanascite™ helped to identify a characteristic feature of tumor aggressiveness. As Cleanascite™ is an aqueous suspension product without harmful solvents, one can use it to challenge cells for responsiveness. This ultimately helps researchers decide whether or not lipids, or factors interacting with lipids, impart characteristic changes in cancer cells. This information will hopefully help our understanding of how to reprogram the tumor microenvironment for therapeutic benefit.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “ Cleanascite™ - Lipid Removal and Cell Response Applications ”, visit:

http://www.biotechsupportgroup.com/v/vspfiles/temp...

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lip...

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact:

Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com